<DOC>
	<DOCNO>NCT00834574</DOCNO>
	<brief_summary>The objective study compare relative bioavailability cefdinir oral suspension 250 mg/5mL ( manufacture distribute TEVA Pharmaceuticals USA ) OMNICEF® oral suspension , 250 mg/5mL ( Abbott ) healthy , adult , non-smoking subject fast condition .</brief_summary>
	<brief_title>Cefdinir Oral Suspension 250 mg/5mL , Fasting</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Cefdinir</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>All subject select study nonsmoker least 18 year age . Subjects BMI ( body mass index ) 19 kg/m² 30 kg/m² ( inclusive ) . Each subject give general physical examination within 28 day initiation study . Such examination include limited blood pressure , general observation , history . Each female subject give serum pregnancy test part prestudy screen process . Adequate blood urine sample obtain within 28 day begin first period end trial clinical laboratory measurement . Clinical laboratory measurement include follow : Hematology : hemoglobin , hematocrit , red blood cell count , platelet , white blood cell count ( differential ) . Clinical Chemistry : creatinine , BUN , glucose , SGOT , SGPT , bilirubin , alkaline phosphatase . Urine Analysis : pH , specific gravity , protein , glucose , ketone , bilirubin , occult blood , cell . HIV Screen HepatitisB , C Screen Drugs Abuse Screen : prestudy dose period checkin Subjects select normal . Electrocardiograms participate subject record initiation study file subject 's case report form . Subjects history alcoholism drug addiction ( past 2 year ) serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma ( past 5 year ) , diabetes , psychosis glaucoma eligible study . Subjects whose clinical laboratory test value outside reference range may retested discretion clinical investigator . If clinical value outside range retesting , subject eligible participate study unless clinical investigator deem result significant . Subjects history allergic response class drug test ( include penicillin , penicillin derivative , cephalosporin product ) exclude study . All subject urine/saliva sample assay presence drug abuse part clinical laboratory screening procedure study period checkin . Subjects found urin/saliva concentration test drug allow participate . Subjects donate blood and/or plasma least thirty ( 30 ) day prior first dose study . Subjects take investigational drug within thirty ( 30 ) day prior first dose study allow participate . Female subject pregnant , breastfeeding , likely become pregnant study allow participate . Female subject child bear potential must either abstain sexual intercourse use reliable barrier method ( e.g . condom , IUD ) contraception course study ( first dose last blood collection ) allow participate . Subjects use implant injected hormonal contraceptive anytime 6 month prior study dose , use oral hormonal contraceptive within 14 day dose allowed participate . All female subject screen pregnancy checkin study period . Subjects positive inconclusive result withdrawn study . Subjects tolerate venipuncture allow participate . Subjects use tobacco form eligible participate study . Three month abstinence require . Subjects difficulty fast consume standard meal allow participate . Subjects clinically significant illness within 4 week prior first dose study allow participate . Subjects use know hepatic enzyme inducer inhibitor within 30 day prior first dose study allow participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>